臨床検査66巻3号

2022年03月発行

今月の特集 「心不全パンデミック」を迎え撃つ！ 心不全のバイオマーカー

心筋トロポニン

著者： 中尾元基¹ 永井利幸¹

所属機関： ¹北海道大学大学院医学研究院循環病態内科学教室

ページ範囲：P.236 - P.242

Point

●心筋トロポニンは急性心筋梗塞の診断目的に開発されたバイオマーカーであるが，心筋障害を直接反映するため心不全患者でも微量の心筋トロポニンが検出される．

●近年，高感度心筋トロポニン測定系の登場によって，基準値以下の微量のトロポニン値も正確に測定することが可能となった．

●高感度心筋トロポニン測定系で検出される微量な心筋トロポニン値によって，心不全患者の予後予測だけでなく，心不全未発症患者の予後予測も可能であることが明らかとなった．

参考文献

1）日本循環器学会，日本心不全学会，日本胸部外科学会，他：日本循環器学会/日本心不全学会合同ガイドライン　急性・慢性心不全診療ガイドライン（2017年改訂版），2021（https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf）（最終アクセス：2021年11月15日）

2）Ebashi S, Endo M, Otsuki I：Control of muscle contraction. Q Rev Biophys　2：351-384，1969

3）Apple FS, Jaffe AS, Collinson P, et al：IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clin Biochem　4：201-203，2014

4）Pascual-Figal DA, Casas T, Ordonez-Llanos J, et al：Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J　163：1002-1010，2012

5）Löwbeer C, Gustafsson SA, Seeberger A, et al：Serum cardiac troponin T in patients hospitalized with heart failure is associated with left ventricular hypertrophy and systolic dysfunction. Scand J Clin Lab Invest　64：667-676，2004

6）Peacock WF 4th, De Marco T, Fonarow GC, et al：Cardiac troponin and outcome in acute heart failure. N Engl J Med　358：2117-2126，2008

7）Kuwabara Y, Sato Y, Miyamoto T, et al：Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. Circ J　71：1047-1051，2007

8）Xue Y, Clopton P, Peacock WF, et al：Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail　13：37-42，2011

9）Aimo A, Januzzi JL Jr, Mueller C, et al：Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. Int J Cardiol　293：137-142，2019

10）Latini R, Masson S, Anand IS, et al：Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation　116：1242-1249，2007

11）McMurray JJ, Packer M, Desai AS, et al：Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med　371：993-1004，2014

12）Solomon SD, McMurray JJV, Anand IS, et al：Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med　381：1609-1620，2019

13）Rørth R, Jhund PS, Kristensen SL, et al：The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail　21：40-49，2019

14）McMurray JJV, Solomon SD, Inzucchi SE, et al：Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med　381：1995-2008，2019

15）Anker SD, Butler J, Filippatos G, et al：Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med　385：1451-1461，2021

16）Pocock SJ, Ferreira JP, Gregson J, et al：Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. Eur Heart J　ehab579，2021

17）Yancy CW, Jessup M, Bozkurt B, et al：2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol　70：776-803，2017

18）Yaku H, Ozasa N, Morimoto T, et al：Demographics, Management, and In-Hospital Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary Real Clinical Practice in Japan- Observations From the Prospective, Multicenter Kyoto Congestive Heart Failure (KCHF) Registry. Circ J　82：2811-2819，2018

19）Myhre PL, O'Meara E, Claggett BL, et al：Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circ Heart Fail　11：e005312，2018

20）Gori M, Senni M, Claggett B, et al：Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. JACC Heart Fail　9：627-635，2021

21）Yancy CW, Jessup M, Biykem B, et al：2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol　62：e147-e239，2013

22）deFilippi CR, de Lemos JA, Christenson RH, et al：Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA　304：2494-2502，2010

23）Yan I, Börschel CS, Neumann JT, et al：High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure: Results From the BiomarCaRE Consortium. JACC Heart Fail　8：401-411，2020

24）Hillis GS, Welsh P, Chalmers J, et al：The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care　37：295-303，2014

25）Finke D, Romann SW, Heckmann MB, et al：High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: a single-centre cohort study. ESC Heart Fail　8：3709-3719

26）Hussein AA, Bartz TM, Gottdiener JS, et al：Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. Heart Rhythm　12：879-885，2015

27）Li L, Selvin E, Hoogeveen RC, et al：6-year change in high sensitivity cardiac troponin T and the risk of atrial fibrillation in the Atherosclerosis Risk in Communities cohort. Clin Cardiol，2021, in press